Health-related quality of life in patients with untreated cavernous malformations of the central nervous system.
anxiety
depression
quality of life
untreated cavernous malformation
Journal
European journal of neurology
ISSN: 1468-1331
Titre abrégé: Eur J Neurol
Pays: England
ID NLM: 9506311
Informations de publication
Date de publication:
02 2021
02 2021
Historique:
received:
11
06
2020
accepted:
05
09
2020
pubmed:
23
9
2020
medline:
13
8
2021
entrez:
22
9
2020
Statut:
ppublish
Résumé
To estimate health-related quality of life (HRQOL) in patients with untreated cavernous malformation of the CNS [cavernous cerebral malformations (CCMs)]. We performed a cross-sectional observational study on patients with CCMs admitted to our department from 1 November 2017 to 10 January 2020 using standardized interviews [short-form-36 questionnaire, hospital anxiety and depression score (HADS-A/D), CCM perception questionnaire]. Included criteria were diagnosis of an untreated CCM and information about the diagnosis in a specialized CCM consultation. Health-related quality of life (HRQOL) data were analyzed and compared to the German normal population. Uni- and multivariate analyses were carried out to identify variables with impact on outcome. Two hundred nineteen (93%) of 229 eligible patients were included. Mean age was 46.3 ± 14.7 (18-86) years; 136 (62%) were female. Ninety-eight (45%) patients presented with symptomatic hemorrhage (SH), and 17 (8%) with repetitive SH. Ninety-two (42%) patients were asymptomatic. Thirty-seven patients (17%) suffered from cavernoma-related epilepsy. Twenty-eight patients (13%) suffered from familial CCMs. Patients showed significantly decreased component scores and subdomain scores compared to the normal population, with effects ranging from small to large. This accounted largely also for asymptomatic patients (except for physical component score and main physical subdomains). Multivariate regression analysis confirmed impact of functional impairment on physical component score. HADS-A was significantly increased. HADS-A/D strongly correlated with mental component score and individual perception of the CCM. Patients with the diagnosis of a CCM showed decreased HRQOL compared to the normal population even when not suffering functional impairment or neurological symptoms. Our data may function as benchmarks in evaluation of different (future) management strategies.
Sections du résumé
BACKGROUND AND PURPOSE
To estimate health-related quality of life (HRQOL) in patients with untreated cavernous malformation of the CNS [cavernous cerebral malformations (CCMs)].
METHODS
We performed a cross-sectional observational study on patients with CCMs admitted to our department from 1 November 2017 to 10 January 2020 using standardized interviews [short-form-36 questionnaire, hospital anxiety and depression score (HADS-A/D), CCM perception questionnaire]. Included criteria were diagnosis of an untreated CCM and information about the diagnosis in a specialized CCM consultation. Health-related quality of life (HRQOL) data were analyzed and compared to the German normal population. Uni- and multivariate analyses were carried out to identify variables with impact on outcome.
RESULTS
Two hundred nineteen (93%) of 229 eligible patients were included. Mean age was 46.3 ± 14.7 (18-86) years; 136 (62%) were female. Ninety-eight (45%) patients presented with symptomatic hemorrhage (SH), and 17 (8%) with repetitive SH. Ninety-two (42%) patients were asymptomatic. Thirty-seven patients (17%) suffered from cavernoma-related epilepsy. Twenty-eight patients (13%) suffered from familial CCMs. Patients showed significantly decreased component scores and subdomain scores compared to the normal population, with effects ranging from small to large. This accounted largely also for asymptomatic patients (except for physical component score and main physical subdomains). Multivariate regression analysis confirmed impact of functional impairment on physical component score. HADS-A was significantly increased. HADS-A/D strongly correlated with mental component score and individual perception of the CCM.
CONCLUSIONS
Patients with the diagnosis of a CCM showed decreased HRQOL compared to the normal population even when not suffering functional impairment or neurological symptoms. Our data may function as benchmarks in evaluation of different (future) management strategies.
Types de publication
Journal Article
Observational Study
Research Support, Non-U.S. Gov't
Langues
eng
Sous-ensembles de citation
IM
Pagination
491-499Informations de copyright
© 2020 The Authors. European Journal of Neurology published by John Wiley & Sons Ltd on behalf of European Academy of Neurology.
Références
Mosnier JF, Brunon J, Nuti C. Histopathology of central nervous system cavernomas. Neurochirurgie 2007; 53(2-3 Pt 2): 131-135. https://doi.org/10.1016/j.neuchi.2007.02.004.
Gross BA, Du R. Hemorrhage from cerebral cavernous malformations: a systematic pooled analysis. J Neurosurg 2017; 126: 1079-1087. https://doi.org/10.3171/2016.3.JNS152419.
Dalyai RT, Ghobrial G, Awad I, et al. Management of incidental cavernous malformations: a review. Neurosurg Focus 2011; 31: E5.
Flemming KD, Graff-Radford J, Aakre J, et al. Population-based prevalence of cerebral cavernous malformations in older adults: Mayo Clinic study of aging. JAMA Neurol 2017; 74: 801-805.
Josephson CB, Leach JP, Duncan R, et al. Seizure risk from cavernous or arteriovenous malformations: prospective population-based study. Neurology 2011; 76: 1548-54.
Akers A, Al-Shahi Salman R, Awad A, et al. Synopsis of guidelines for the clinical management of cerebral cavernous malformations: Consensus recommendations based on systematic literature review by the Angioma Alliance Scientific Advisory Board Clinical Experts Panel. Neurosurgery 2017; 80: 665-680.
Al-Shahi Salman R, Hall JM, Horne MA, et al. Untreated clinical course of cerebral cavernous malformations: a prospective, population-based cohort study. Lancet Neurol 2012; 11: 217-224.
Brown RD, Wiebers DO, Torner JC, O'Fallon WM. Frequency of intracranial hemorrhage as a presenting symptom and subtype analysis: a population-based study of intracranial vascular malformations in Olmsted Country, Minnesota. J Neurosurg 1996; 85: 29-32.
Poorthuis MHF, Rinkel LA, Lammy S, Al-Shahi Salman R. Stereotactic radiosurgery for cerebral cavernous malformations: A systematic review. Neurology 2019; 93: e1971-e1979.
Flemming KD, Lanzino G. Stereotactic radiosurgery for cavernous malformations: natural history or treatment effect? Neurology 2019; 93: 921-922.
Poorthuis MH, Klijn CJ, Algra A, Rinkel GJ, Al-Shahi Salman R. Treatment of cerebral cavernous malformations: a systematic review and meta-regression analysis. J Neurol Neurosurg Psychiatry 2014; 85: 1319-1323.
Rinkel LA. Radiosurgical, neurosurgical, or no intervention for cerebral cavernous malformations: a decision analysis. In: Salman RA-S, editor. Int J Stroke 2019; 14: 939-945.
Horne MA, Flemming KD, Su IC, et al. Clinical course of untreated cerebral cavernous malformations: a meta-analysis of individual patient data. Lancet Neurol 2016; 15: 166-173.
Polster SP, Cao Y, Carroll T, et al. Trial readiness in cavernous angiomas with symptomatic hemorrhage (CASH). Neurosurgery 2019; 84: 954-964.
Al-Shahi Salman R, Kitchen N, Thomson J, et al. Top ten research priorities for brain and spine cavernous malformations. Lancet Neurol 2016; 15: 354-355.
Al-Shahi Salman R, Berg MJ, Morrison L, Awad IA, Board AASA. Hemorrhage from cavernous malformations of the brain: definition and reporting standards. Angioma Alliance Scientific Advisory Board. Stroke 2008; 39: 3222-3230.
Bicalho VC, Bergmann A, Domingues F, Frossard JT, de Souza JPBM. Cerebral cavernous malformations: patient-reported outcome validates conservative management. Cerebrovasc Dis 2017; 44: 313-319.
Kumar S, Lanzino G, Flemming KD. Affected health domains in patients with brainstem cavernous malformations. Acta Neurochir (Wien) 2019; 161: 2521-2526.
Cornelius JF, Kurten K, Fischer I, Hanggi D, Steiger HJ. Quality of life after surgery for cerebral cavernoma: brainstem versus nonbrainstem location. World Neurosurg 2016; 95: 315-321.
Dukatz T, Sarnthein J, Sitter H, et al. Quality of life after brainstem cavernoma surgery in 71 patients. Neurosurgery 2011; 69: 689-695.
The World Health Organization Quality of Life assessment (WHOQOL): position paper from the World Health Organization. Soc Sci Med 1995; 41: 1403-1409.
Cella DF, Bonomi AE. Measuring quality of life: 1995 update. Oncology (Williston Park) 1995; 9(11 Suppl.): 47-60.
Khanna D, Tsevat J. Health-related quality of life-an introduction. Am J Manag Care 2007; 13(Suppl. 9): S218-S223.
Weimar C, Kurth T, Kraywinkel K, et al. Assessment of functioning and disability after ischemic stroke. Stroke 2002; 33(8): 2053-2059.
Ali M, Fulton R, Quinn T, Brady M, Collaboration V. How well do standard stroke outcome measures reflect quality of life? A retrospective analysis of clinical trial data. Stroke 2013; 44: 3161-3165.
Contopoulos-Ioannidis DG, Karvouni A, Kouri I, Ioannidis JP. Reporting and interpretation of SF-36 outcomes in randomised trials: systematic review. BMJ 2009; 338: a3006.
Kim DH, Haney CL, Van Ginhoven G. Utility of outcome measures after treatment for intracranial aneurysms: a prospective trial involving 520 patients. Stroke 2005; 36: 792-796.
Dammann P, Wittek P, Darkwah Oppong M, et al. Relative health-related quality of life after treatment of unruptured intracranial aneurysms: long-term outcomes and influencing factors. Ther Adv Neurol Disord 2019; 12: 1756286419833492.
Hinz A, Brahler E. Normative values for the hospital anxiety and depression scale (HADS) in the general German population. J Psychosom Res. 2011; 71: 74-78.
McHorney CA, Ware JE. Construction and validation of an alternate form general mental health scale for the Medical Outcomes Study Short-Form 36-Item Health Survey. Med Care 1995; 33: 15-28.
Ware JE, Kosinski M, Bayliss MS, McHorney CA, Rogers WH, Raczek A. Comparison of methods for the scoring and statistical analysis of SF-36 health profile and summary measures: summary of results from the Medical Outcomes Study. Med Care 1995; 33(4 Suppl.): AS264-AS279.
Taslimi S, Modabbernia A, Amin-Hanjani S, Barker FG 2nd, Macdonald RL. Natural history of cavernous malformation: Systematic review and meta-analysis of 25 studies. Neurology 2016; 86: 1984-1991.
Li D, Hao SY, Jia GJ, Wu Z, Zhang LW, Zhang JT. Hemorrhage risks and functional outcomes of untreated brainstem cavernous malformations. J Neurosurg 2014; 121: 32-41.